La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Avecho Biotechnology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Avecho Biotechnology..

Avecho Biotechnology (OTC:AVEFF) Azioni, Catena delle Opzioni

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

AVECHO BIOTECHNOLOGY LTD by Avecho Biotechnology Ltd.

Avecho Biotechnology Ltd

WIIM

Sherwin-Williams shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

NVDA

NVIDIA shares are trading higher after it was announced that the company will join the Dow Jones Industrial Average.

News

Offerings

RDZN

Roadzen Files For Mixed Shelf Of Up To $100M

Contracts

ITRM

Iterum Therapeutics Notified Pfizer, Electing To Defer Milestone Payment For 2 Years For ORLYNVAH, Or Until Oct 25, 2026

The Symplicity &#x2122; blood pressure procedure offers patients a new adjunct approach to lowering blood pressure&nbsp;
GALWAY, Ireland, Nov. 1, 2024 /PRNewswire/ -- Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), a global leader in healthcare technology, today announced that the Centers for Medicare &amp; Medicaid Services (CMS) has granted transitional pass-through (TPT) payment for the Medtronic Symplicity Spyral&#x2122;&nbsp;renal denervation (RDN) catheter, used in the Symplicity&#x2122;&nbsp;blood pressure procedure, under the Medicare Hospital Outpatient Prospective Payment System. TPT payment, which will be effective for up to three years beginning January 1, 2025, aims to support patient access to new and innovative technology, including devices granted Breakthrough Device Designations like the Symplicity Spyral RDN system.

Biotech

General

CMS grants Transitional Pass-Through Payment For Medtronic Symplicity Spyral Renal Denervation Catheter; Will Be Effective For Up To Three Years Beginning January 1, 2025

Titan International Files For Offering Of Up To 11.92M Shares By The Selling Stockholders

NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/NB#NASDAQ">NB</a>) today announced it has commenced a proposed underwritten public offering in the United States (the "Registered Offering"). Concurrently, the Company has also commenced a private placement (the "Private Offering" and, together with the Registered Offering, the "Offerings").
The Registered Offering consists of common shares and warrants to purchase common shares and is subject to market conditions. There can be no assurance as to whether or when the Registered Offering may be completed, or as to the actual size, pricing or other terms of the Registered Offering. In addition, the Company intends to grant the underwriter a 45-day over-allotment option to purchase up to an additional 15 percent of the number of initial common shares and/or an additional 15 percent of the number of initial warrants offered in the Registered Offering.
The Private Offering consists of common shares and warrants to purchase common shares. There can be no assurance as to whether or when the Private Offering may be completed, or as to the actual size, pricing or other terms of the Private Offering. Completion of the Private Offering is not contingent on completion of the Registered Offering and completion of the Registered Offering is not contingent on the completion of the Private Offering.
Maxim Group LLC is acting as sole book-running manager and underwriter for the Registered Offering.
NioCorp currently intends to use the net proceeds from the Offerings for working capital and general corporate purposes, including to (i) advance its efforts to launch construction of a critical minerals project in Southeast Nebraska (the "Elk Creek Project") and move it to commercial operation and (ii) repay all amounts outstanding under the Company's $2.0 million non-revolving multiple draw credit facility (the "Smith Credit Facility") available pursuant to the Loan Agreement, dated September 11, 2024, by and between the Company and its Chief Executive Officer, President and Executive Chairman, Mark Smith. The Smith Credit Facility will continue to be available to the Company following the close of the Offerings.
The Registered Offering is subject to customary closing conditions.

NioCorp Announces Commencement Of Proposed Underwritten Public Offering Of Common Shares & Warrants; No Size Or Amount Disclosed

CHWY

Chewy shares are trading higher after it was announced that the company will join the S&P MidCap 400 prior to the opening of trading on Wednesday, November 6, 2024.

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475162/1475162_djiadjuaintcdowaes.pdf</a>

Markets

NVIDIA And Sherwin-Williams Set To Join Dow Jones Industrial Average; Vistra To Join Dow Jones Utility Average

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241101-1475163/1475163_srcl4.pdf</a>

SRCL

Chewy Set to Join S&P MidCap 400; Chewy Will Replace Stericycle Inc In The S&P MidCap 400 Effective Prior To The Opening Of Trading On Wednesday, November 6

<a href="https://www.bloomberg.com/news/articles/2024-11-01/tesla-sells-499-million-of-debt-backed-by-solar-equipment-loans">https://www.bloomberg.com/news/articles/2024-11-01/tesla-sells-499-million-of-debt-backed-by-solar-equipment-loans</a>
Tesla Inc. sold $499 million of bonds backed by loans offered to customers buying solar equipment.

Financing

Asset Sales

TSLA

'Tesla Sells $499M Of Debt Backed by Solar Equipment Loans' - Bloomberg News

EVTV

Envirotech Vehicles Files Prospectus Relates To Resale, From Time To Time, Of Up To 13.6M Shares Of Common Stock

Global

BORR

Borr Drilling Limited Announces Voluntary Delisting From Oslo Stock Exchange; Co's Shares Will Be Delisted From OSE As Of 31 December 2024

ONCO

Onconetix Files For Resale Of Up To 10,586,556 Shares By The Selling Stockholders; Offering Up To 6.25M Shares Of Common Stock

- SEC Filing&nbsp;
On October 30, 2024, the Company received a letter from Nasdaq notifying the Company that, the Company had not regained compliance with the MVLS Requirement within the Cure Period. As a result, Nasdaq has determined to delist the Company's securities from Nasdaq on November 8, 2024, subject to the Company's right to appeal described below.
&nbsp;
On October 31, 2024, the Company requested a hearing to appeal such determination before a panel (the "Hearings Panel"). The hearing request will stay the suspension of the trading of the Company's common stock pending such hearing or any extension provided by the Hearings Panel.
&nbsp;
At such hearing, the Company intends to submit a plan to regain compliance with the MVLS Requirement and with other deficiencies in its compliance with Nasdaq listing requirements that have been previously disclosed, including the failure to comply with the minimum bid price requirement disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 25, 2024.
&nbsp;
No assurances can be provided that the Company will obtain a favorable decision from the Hearings Panel, and/or that the Company will be able to regain or maintain compliance with Nasdaq listing's rules.

CERO

CERo Therapeutics Received A Letter From Nasdaq Notifying The Company That It Had Not Regained Compliance With The MVLS Requirement Within The Cure Period; Nasdaq Has Determined To Delist The Company's Securities From Nasdaq On November 8, 2024; On October 31, 2024, The Co Requested A Hearing To Appeal The Determination Before A Panel

BNTC

Benitec Biopharma Files For Mixed Shelf Of Up To $125M

Super League Enterprise 13G Filing Shows Infinite Reality, Inc. Reported A 9.2% Stake In The Co As Of October 29, 2024

ITT Files For Mixed Shelf; Size Not Disclosed

ADAP

Adaptimmune Therapeutics Receives Nasdaq Notice For Non-Compliance With Minimum Bid Price

Marti Technologies, Inc. ("Marti" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRT#NYSE">MRT</a>), Türkiye's leading mobility super app, today announced that it has appointed Deniz Terlemez as its new Interim Chief Financial Officer ("CFO"), effective November 1, 2024. Deniz Terlemez succeeds Oguz Erkan, the Company's former CFO. Mr. Terlemez served as the Company's Finance Director before his appointment as Interim CFO.

Management

Marti Technologies Appoints  Deniz Terlemez As New Interim Chief Financial Officer, Effective November 1, 2024

Avecho Biotechnology

Comments

Avecho Biotechnology

Avecho Biotechnology (AVEFF) Opzioni

Loading...

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO